The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
C-reactive protein (CRP) is an acute-phase protein that is produced in large amounts by hepatocytes, upon stimulation by the cytokines interleukin-6, tumor-necrosis-factor-alpha and interleukin-1beta, during an acute-phase response. CRP is an objective marker of inflammation and, in gastrointestinal diseases such as Crohn's disease and acute pancreatitis, its levels correlate well with clinical disease activity. In contrast to its use as a marker in Crohn's disease, however, CRP is a less reliable marker of inflammation and disease activity in patients with ulcerative colitis, except perhaps for severe, extensive colitis. The increased production of CRP after an acute-phase stimulus, such as active gut inflammation, might explain why strong anti-inflammatory agents, such as anti-tumor-necrosis-factor-alpha antibodies and other biologic agents, work particularly well in patients with increased levels of CRP. CRP is also useful as a laboratory marker to predict prognosis and relapse in patients with Crohn's disease and acute pancreatitis. Elevated CRP levels have been associated with an increased risk of colorectal cancer and are a marker of poor prognosis, indicating more advanced disease and, possibly, reduced survival. An important question that remains is how often CRP levels should be measured. Until there are more data, the use of CRP and of other biomarkers should be seen as an additional tool that aids clinical observation and physical examination, but that cannot repla…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The CRP level is often used in chronic inflammatory diseases as a marker of active inflammation; it is typically understood to be an acute phase reactant 19 .”
From The Manitoba IBD Index: Evidence for a New and Simple Indicator of IBD Activity (2009) · cites this paper as [19]
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Self-citationTargan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Self-citationDanesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953 · cited 1×
“68), it was less strong as a risk factor compared with well-established risk factors, such as increased cholesterol and cigarette smoking”
BackgroundInfliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,752 · cited 1×
“The anti-TNFα antibodies are very efficacious in patients with Crohn's disease”
BackgroundSelf-citationThe Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422603 · Cited by 2,526 · cited 1×
“Further evidence that inflammation is important in tumorigenesis is provided by the ability of anti-inflammatory drugs to reduce polyp formation and colorectal cancer risk”
BackgroundInfliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,226 · cited 1×
“The anti-TNFα antibodies are very efficacious in patients with Crohn's disease”
BackgroundSelf-citationTreatment of Colonic and Rectal Adenomas with Sulindac in Familial Adenomatous Polyposis
Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R., & Offerhaus, G. J. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305063281805 · Cited by 1,717 · cited 1×
“Further evidence that inflammation is important in tumorigenesis is provided by the ability of anti-inflammatory drugs to reduce polyp formation and colorectal cancer risk”
BackgroundA Randomized Trial of Aspirin to Prevent Colorectal Adenomas
Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., McKeown-Eyssen, G., Summers, R. W., Rothstein, R., Burke, C. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021735 · Cited by 1,416 · cited 1×
“Further evidence that inflammation is important in tumorigenesis is provided by the ability of anti-inflammatory drugs to reduce polyp formation and colorectal cancer risk”
BackgroundPredicting outcome in severe ulcerative colitis.
Travis, S. P., Farrant, J. M., Ricketts, C., Nolan, D. J., Mortensen, N. M., Kettlewell, M. G., & Jewell, D. P. (1996) · Gut · doi:10.1136/gut.38.6.905 · Cited by 788
Vigushin, D. M., Pepys, M. B., & Hawkins, P. N. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116336 · Cited by 636 · cited 1×
“infection, inflammation, trauma, childbirth, severe burns, stress and neoplasia), however, the liver has a large capacity to increase the baseline production of CRP by upregulating its transcription in hepatocytes”
Background
Research works printed but not linked: 1
- Rutgeerts P et al. (2003) Subanalysis from a phase 3 study on the evaluation of natalizumab in active Crohn's disease [Abstract]. Gut 52 (Suppl): A239
Cited by
Maaser, C., Sturm, A., Vavricka, S. R., Kucharzik, T., Fiorino, G., Annese, V., Calabrese, E., Baumgart, D. C., Bettenworth, D., Borralho Nunes, P., et al. (2019) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjy113 · Cited by 1,823
Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910
Dignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498
Dignass, A., Eliakim, R., Magro, F., Maaser, C., Chowers, Y., Geboes, K., Mantzaris, G., Reinisch, W., Colombel, J.-F., Vermeire, S., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.003 · Cited by 888
Self-citationStange, E. F., Travis, S. P. L., Vermeire, S., Reinisch, W., Geboes, K., Barakauskiene, A., Feakins, R., Fléjou, J. F., Herfarth, H., Hommes, D. W., et al. (2008) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2007.11.001 · Cited by 555
Self-citationMcMillan, D. C. (2008) · Proceedings of the Nutrition Society · doi:10.1017/s0029665108007131 · Cited by 472
“C-reactive protein, because of its sensitivity, specificity and reproducibility of analysis in hospital laboratories, is most commonly used to assess the magnitude (whether acute or chronic) of the systemic inflammatory response((28,31)).”
Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse
Gisbert, J. P., Bermejo, F., Pérez-Calle, J.-L., Taxonera, C., Vera, I., McNicholl, A. G., Algaba, A., López, P., López-Palacios, N., Calvo, M., et al. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20933 · Cited by 315
Mesenteric fat in Crohn’s disease: a pathogenetic hallmark or an innocent bystander?
Peyrin-Biroulet, L., Chamaillard, M., Gonzalez, F., Beclin, E., Decourcelle, C., Antunes, L., Gay, J., Neut, C., Colombel, J.-F., & Desreumaux, P. (2007) · Gut · doi:10.1136/gut.2005.082925 · Cited by 264
Predicting relapse in Crohn’s disease: a biopsychosocial model
Bitton, A., Dobkin, P. L., Edwardes, M. D., Sewitch, M. J., Meddings, J. B., Rawal, S., Cohen, A., Vermeire, S., Dufresne, L., Franchimont, D., et al. (2008) · Gut · doi:10.1136/gut.2007.134817 · Cited by 254
“CRP hepatic production is regulated by IL6, and thus both are highly correlated.(41) IL6 may not have been identified as a predictor of relapse because in the multivariate analysis it was accounted for by CRP.”
BackgroundSelf-citationGisbert, J. P., & McNicholl, A. G. (2009) · Digestive and Liver Disease · doi:10.1016/j.dld.2008.05.008 · Cited by 238
Villarán, R. F., Espinosa‐Oliva, A. M., Sarmiento, M., De Pablos, R. M., Argüelles, S., Delgado‐Cortés, M. J., Sobrino, V., Van Rooijen, N., Venero, J. L., Herrera, A. J., et al. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06879.x · Cited by 214
“An increase of plasma CRP had also been described in inflammatory bowel disease (Vermeire et al. 2004, 2005).”
BackgroundDisease monitoring in inflammatory bowel disease
Chang, S. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i40.11246 · Cited by 183
Jürgens, M., Mahachie John, J. M., Cleynen, I., Schnitzler, F., Fidder, H., van Moerkercke, W., Ballet, V., Noman, M., Hoffman, I., van Assche, G., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.02.008 · Cited by 189
Self-citationC-Reactive Protein and High-Sensitivity C-Reactive Protein: An Update for Clinicians
Windgassen, E. B., Funtowicz, L., Lunsford, T. N., Harris, L. A., & Mulvagh, S. L. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.01.2252 · Cited by 170
“In 2 studies, none of the patients with functional symptoms had an elevated CRP, whereas all patients with Crohn’s disease and about 50% to 60% of patients with ulcerative colitis had elevation of the inflammatory marker.(31) In patients with pancreatitis, CRP becomes elevated with increasing severity of illness.”
BackgroundInfluentialDoes fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
García-Sánchez, V., Iglesias-Flores, E., González, R., Gisbert, J. P., Gallardo-Valverde, J. M., González-Galilea, Á., Naranjo-Rodríguez, A., de Dios-Vega, J. F., Muntané, J., & Gómez-Camacho, F. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.09.008 · Cited by 163
Interaction of obesity and inflammatory bowel disease
Harper, J. W., & Zisman, T. L. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i35.7868 · Cited by 158
Role of Obesity, Mesenteric Adipose Tissue, and Adipokines in Inflammatory Bowel Diseases
Bilski, J., Mazur-Biały, A. I., Wójcik-Grzybek, D., Surmiak, M., Magierowski, M., Śliwowski, Z., Pajdo, R., Kwiecień, S., Danielak, A., Ptak‐Belowska, A., et al. (2019) · Biomolecules · doi:10.3390/biom9120780 · Cited by 159
“The mWAT is an important source of CRP in CD patients, and its production by mesenteric adipocytes may be triggered by local inflammation and bacterial translocation to mWAT [102,116].”
BackgroundKolkhir, P., Altrichter, S., Hawro, T., & Maurer, M. (2017) · Allergy · doi:10.1111/all.13352 · Cited by 145
Kermanizadeh, A., Pojana, G., Gaiser, B. K., Birkedal, R. K., Bilaničová, D., Wallin, H., Jensen, K. A., Sellergren, B., Hutchison, G. R., Marcomini, A., et al. (2012) · Nanotoxicology · doi:10.3109/17435390.2011.653416 · Cited by 130
“There was no significant increase or decrease in the production of IL-6, TNF-a or CRP after the exposure of the C3A cells to any of the selected NMs (data not shown).”
BackgroundInfluentialIgG and Fcγ Receptors in Intestinal Immunity and Inflammation
Castro‐Dopico, T., & Clatworthy, M. R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00805 · Cited by 144
“In particular, CRP mediates FcγRIIA-dependent internalization of damaged cells, self-antigens and microbes by human monocytes and neutrophils, via binding to phosphorylcholine moieties, chromatin, and histones (29, 30).”
BackgroundGisbert, J. P., McNicholl, A. G., & Gomollón, F. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20920 · Cited by 132
The Manitoba IBD Index: Evidence for a New and Simple Indicator of IBD Activity
Clara, I., Lix, L. M., Walker, J. R., Graff, L. A., Miller, N., Rogala, L., Rawsthorne, P., & Bernstein, C. N. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.197 · Cited by 119
“Biological markers and medication use The CRP level is often used in chronic inflammatory diseases as a marker of active inflammation; it is typically understood to be an acute phase reactant (”
BackgroundMocellin, M. C., Camargo, C. D. Q., Nunes, E. A., Fiates, G. M. R., & Trindade, E. B. S. D. M. (2015) · Clinical Nutrition · doi:10.1016/j.clnu.2015.04.013 · Cited by 119
“On the other hand, IL-6 is the main stimulus for production of CRP by the liver [41].”
BackgroundMetabolic Inflammation in Inflammatory Bowel Disease: Crosstalk Between Adipose Tissue and Bowel
Gonçalves, P., Magro, F., & Martel, F. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000209 · Cited by 121
“Unlike UC, active CD is commonly associated with a significant CRP increase.(168,169) Moreover, a cor-”
BackgroundBoncler, M. A., Wu, Y., & Watała, C. W. (2019) · Molecules · doi:10.3390/molecules24112062 · Cited by 120
High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment
Magro, F., Rodrigues‐Pinto, E., Santos‐Antunes, J., Boas, F. V., Lopes, S., Nunes, A. C. R., Dias, C. C., & Macedo, G. (2013) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2013.07.005 · Cited by 104
Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?
ARGOLLO, M. C., Kotze, P. G., Ramaswamy, P. K., & D’Haens, G. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0352-2 · Cited by 90
Preoperative thrombocytosis is associated with survival after surgery for colorectal cancer
Ishizuka, M., Nagata, H., Takagi, K., Iwasaki, Y., & Kubota, K. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23163 · Cited by 93
“IL-6 stimulates hepatocytes and exerts an adverse effect, not only down-regulating the synthesis of albumin [7] but also up-regulating that of CRP [8,9].”
BackgroundSerum C-reactive protein is a useful marker to exclude anastomotic leakage after colorectal surgery
Messias, B. A., Botelho, R. V., Saad, S. S., Mocchetti, E. R., Turke, K. C., & Waisberg, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-58780-3 · Cited by 90
Brown, S. R., Fearnhead, N. S., Faiz, O. D., Abercrombie, J. F., Acheson, A. G., Arnott, R. G., Clark, S. K., Clifford, S., Davies, J., Davies, M. M., et al. (2018) · Colorectal Disease · doi:10.1111/codi.14448 · Cited by 87
Espéli, M., Smith, K. G. C., & Clatworthy, M. R. (2015) · Immunological Reviews · doi:10.1111/imr.12368 · Cited by 83
“Circulating CRP levels are used as a biomarker for disease activity in a number of autoimmune and inflammatory diseases, including Crohn’s disease and atherosclerosis (142, 143).”
BackgroundFecal calprotectin: its scope and utility in the management of inflammatory bowel disease
Ikhtaire, S., Shajib, M. S., Reinisch, W., & Khan, W. I. (2016) · Journal of Gastroenterology · doi:10.1007/s00535-016-1182-4 · Cited by 88
“Therefore, its presence in feces indicates neutrophil migration to and infiltration in the intestinal tract [8, 20, 21].”
BackgroundAbraham, T., & Romani, A. (2022) · Cells · doi:10.3390/cells11091548 · Cited by 98
“C-reactive protein is produced by hepatocytes following an increase in the levels of inflammatory cytokines such as interleukin-6, TNF-α, and interleukin-1β, and it is an established inflammatory marker released under various pathological conditions [62].”
BackgroundTiele, A., Wicaksono, A. N., Kansara, J., Arasaradnam, R. P., & Covington, J. A. (2019) · Biosensors · doi:10.3390/bios9020055 · Cited by 77
“CRP correlates reasonably well with CD activity, but has poor sensitivity [21].”
BackgroundDragoni, G., Innocenti, T., & Galli, A. (2020) · Digestive Diseases · doi:10.1159/000511641 · Cited by 77
Crozier, J. E. M., Leitch, E. F., McKee, R. F., Anderson, J. H., Horgan, P. G., & McMillan, D. C. (2008) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2007.12.052 · Cited by 71
“There is also a consistent link between the presence of a systemic inflammatory response and comorbid disease ((26)).”
BackgroundMucosal healing in inflammatory bowel disease: Treatment efficacy and predictive factors
Papi, C., Fascì-Spurio, F., Rogai, F., Settesoldi, A., Margagnoni, G., & Annese, V. (2013) · Digestive and Liver Disease · doi:10.1016/j.dld.2013.07.006 · Cited by 70
Local and systemic effects of interleukin‐6 (IL‐6) in inflammation and cancer
Rose‐John, S. (2021) · FEBS Letters · doi:10.1002/1873-3468.14220 · Cited by 65
Kim, E. Y., Yim, H. W., Park, C. H., & Song, K. Y. (2016) · Surgical Endoscopy · doi:10.1007/s00464-016-5272-4 · Cited by 60
“It is produced in the liver and is stimulated by the cytokines IL-6, tumor-necrosis-factor-a, and IL-1 [26, 27].”
BackgroundTenascin‐W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients
Degen, M., Brellier, F., Schenk, S., Driscoll, R. M., Zaman, K., Stupp, R., Tornillo, L., Terracciano, L., Chiquet‐Ehrismann, R., Rüegg, C., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23417 · Cited by 62
“Moreover, high serum tenascin-C levels were clearly correlated with noncancerous liver diseases including hepatitis and liver cirrhosis, and with elevated levels of Creactive protein (CRP),(21) an acute phase protein expressed as a consequence of infection, tissue damage or other inflammatory conditions.(30,31)”
BackgroundMode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases
Tilg, H., Moschen, A. R., & Kaser, A. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.7.1051 · Cited by 55
Gallus, S., Lugo, A., Suatoni, P., Taverna, F., Bertocchi, E., Boffi, R., Marchianò, A. V., Morelli, D., & Pastorino, U. (2018) · Scientific Reports · doi:10.1038/s41598-018-29867-9 · Cited by 55
[Diagnostic guideline of ulcerative colitis].
Choi, C. H., Jung, S.-A., Lee, B., Lee, K., Kim, J. S., & Han, D. S. (2009) · PubMed · Cited by 59
Kasaian, M. T., Page, K. M., Fish, S. C., Brennan, A., Cook, T. A., Moreira, K. E., Zhang, M., Jesson, M. I., Marquette, K., Agostinelli, R., et al. (2014) · Immunology · doi:10.1111/imm.12319 · Cited by 57
Ananthakrishnan, A. N., Cheng, S., Cai, T., Cagan, A., Gainer, V. S., Szolovits, P., Shaw, S. Y., Churchill, S. E., Karlson, E. W., Murphy, S. N., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.12.030 · Cited by 53
Faghfoori, Z., Shakerhosseini, R., Navai, L., Somi, M. H., Nikniaz, Z., & Abadi, A. (2014) · Europe PMC (PubMed Central) · doi:10.5681/hpp.2014.015 · Cited by 51
Leitner, G. C., & Vogelsang, H. (2016) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v7.i1.5 · Cited by 58
Inflammatory mediators profile in patients hospitalized with COVID-19: A comparative study
Tufa, A., Gebremariam, T. H., Manyazewal, T., Getinet, T., Webb, D., Hellström, P. M., & Genet, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.964179 · Cited by 50
“Age, Years, Median (IQR) 24 (20-55) 50 (20-86) 32 (20-78) 60 (22-86) <0.”
BackgroundPapel de los marcadores biológicos en la enfermedad inflamatoria intestinal
Gisbert, J. P., González‐Lama, Y., & Maté, J. (2007) · Gastroenterología y Hepatología · doi:10.1157/13100073 · Cited by 56
Pararasa, C., Zhang, N., Tull, T. J., Chong, M. H. A., Siu, J. H. Y., Guesdon, W., Chavele, K.-M., Sanderson, J. D., Langmead, L., Kok, K. B., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00361 · Cited by 46
“Biological remission was defined as CRP <5 mg/l (31).”
BackgroundKofla-Dłubacz, A., Matusiewicz, M., Krzesiek, E., Noga, L., & Iwańczak, B. M. (2014) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/37031 · Cited by 43
“Elevation of CRP is reported in 70%–100% of patients with active inflammation in the course of CD and 50%–60% of patients with UC [22, 23].”
BackgroundHarlid, S., Gunter, M. J., & Guelpen, B. R. V. (2021) · Cancers · doi:10.3390/cancers13174406 · Cited by 44
“The inflammatory protein included in most studies was CRP, a common marker of acute inflammation [42].”
BackgroundKruis, W., Katalinic, A., Klugmann, T., Franke, G., Weismüller, J., Leifeld, L., Ceplis-Kastner, S., Reimers, B., & Bokemeyer, B. (2012) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2012.10.012 · Cited by 43
A Practical Marker to Determining Acute Severe Ulcerative Colitis: CRP / Albumin Ratio
Sayar, S. (2018) · Northern Clinics of Istanbul · doi:10.14744/nci.2018.78800 · Cited by 43
“5 mg/dl and the stool frequency of 3–8/day are strongly predictive of colectomy [4, 18, 19].”
BackgroundChiu, H., Lin, J., Chen, T. H.-H., Lee, Y., Chiu, Y., Liang, J., Shun, C., & Wu, M. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01952.x · Cited by 42
“CRP is an objective marker of inflammation and has been reported to correlate well with the clinical disease activity of Crohn's disease”
Kim, E. Y., Yim, H. W., Park, C. H., & Song, K. Y. (2016) · Surgical Endoscopy · doi:10.1007/s00464-016-5307-x · Cited by 39
Mori, K., Toiyama, Y., Saigusa, S., Fujikawa, H., Hiro, J., Kobayashi, M., Ohi, M., Araki, T., Inoue, Y., Tanaka, K., et al. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3648-2 · Cited by 39
“However, although CRP represents an excellent biomarker for oncological outcome, we should be aware of its limitations; CRP levels cannot discriminate between patients with several cancers, including CRC, and those with inflammatory conditions such as inflammatory bowel disease, collagen disease, rheumatic disease, an…”
BackgroundIncreased Expression of Long Pentraxin PTX3 in Inflammatory Bowel Diseases
Kato, S., Ochiai, M., Sakurada, T., Ohno, S., Miyamoto, K., Sagara, M., Ito, M., Takeuchi, K., Imaki, J., Itoh, K., et al. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-007-0075-z · Cited by 41
Rajamanickam, A., Munisankar, S., Bhootra, Y., Dolla, C., Nutman, T. B., & Babu, S. (2016) · Infection and Immunity · doi:10.1128/iai.00772-16 · Cited by 37
“The prevalence of increased acute-phase protein concentrations during episodes of inflammation is used as a supporting prognostic and diag-Received nostic tool for inflammatory gastrointestinal diseases (4).”
de Jong, D. C., Löwenberg, M., Koumoutsos, I., Ray, S., Mawdsley, J. E. D., Anderson, S., Sanderson, J. D., Gecse, K. B., Ponsioen, C. Y., D’Haens, G., et al. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy325 · Cited by 35
Aurozyme: A Revolutionary Nanozyme in Colitis, Switching Peroxidase‐Like to Catalase‐Like Activity
Kim, H. S., Lee, S., & Lee, D. Y. (2023) · Small · doi:10.1002/smll.202302331 · Cited by 36
Kim, D. B., Lee, K., Lee, J. M., Chung, Y. Y., Sung, H. J., Paik, C. N., Chung, W. C., Jung, J., & Choi, H. J. (2015) · Gastroenterology Research and Practice · doi:10.1155/2016/5832051 · Cited by 35
C-reactive protein and colorectal adenoma in the CLUE II cohort
Tsilidis, K. K., Erlinger, T. P., Rifai, N., Hoffman, S. C., Hoffman-Bolton, J., Helzlsouer, K. J., & Platz, E. A. (2008) · Cancer Causes & Control · doi:10.1007/s10552-008-9117-x · Cited by 35
“However, circulating C-reactive protein concentration may be reflective of focal necrosis in growing colorectal adenocarcinomas or of the immune response to advanced colorectal cancer, which would account for why C-reactive protein has been shown to be strongly positively associated with colorectal cancer prognosis […”
BackgroundSadowska‐Krępa, E., Rozpara, M., Rzetecki, A., Bańkowski, S., Żebrowska, A., & Pilch, W. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249183 · Cited by 31
“Crohn’s disease), or acute pancreatitis [33] can be reliably detected by CRP.”
BackgroundGuidelines for the Management of Crohn's Disease
Ye, B. D., Yang, S., Shin, S. J., Lee, K., Jang, B. I., Cheon, J. H., Choi, C. H., Kim, Y., & Lee, H. (2012) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2012.59.2.141 · Cited by 31
Champion, J. K., & Williams, M. (2006) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2006.01.013 · Cited by 29
Yuan, S., Sun, Y., Tan, X. W., Geng, J., Sun, J., Chen, X., Yu, L., Wang, J., Zhou, X., Hesketh, T. M., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17285 · Cited by 28
C-reactive protein in Crohn’s disease: how informative is it?
Magro, F., Sousa, P., & Ministro, P. (2014) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2014.893821 · Cited by 29
Administration of anti-Reg I and anti-PAPII antibodies worsens pancreatitis.
Viterbo, D., Callender, G., DiMaio, T., Mueller, C. M., Smith-Norowitz, T. A., Zenilman, M. E., & Bluth, M. H. (2009) · PubMed · Cited by 24
Ishihara, S., Tada, Y., Kawashima, K., Kataoka, M., Sonoyama, H., Yamashita, N., Oka, A., Kusunoki, R., Fukuba, N., Mishima, Y., et al. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2017.12.010 · Cited by 23
Janssen, K. M. J., Hop, H., Vissink, A., Dijkstra, G. D. H., de Smit, M. J., Brouwer, E., & Westra, J. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17218054 · Cited by 23
“Although CD and UC are both inflammatory diseases, CRP is a less reliable marker of inflammation and disease activity in patients with UC, perhaps except for severe, extensive colitis [30].”
BackgroundGuidelines for the Management of Crohn's Disease
Ye, B. D., Yang, S., Shin, S. J., Lee, K., Jang, B. I., Cheon, J. H., Choi, C. H., Kim, Y.-H., & Lee, H. (2012) · Intestinal Research · doi:10.5217/ir.2012.10.1.26 · Cited by 23
Kaur, A., Have, G. A. M. T., Hritzo, B. A., Deutz, N. E. P., Olsen, C. H., & Moroni, M. (2018) · International Journal of Radiation Biology · doi:10.1080/09553002.2018.1552377 · Cited by 23
“This study illustrated the damaging effects of PBI on GI function parameters such as food tolerance, digestion, absorption, and mucosal function and highlighted the response of biomarkers namely, IGF-1 and CRP, following abdominal irradiation.”
BackgroundInfluentialHuang, C., Teng, H., Chien, C., Lin, J.-K., & Yang, S.-H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065117 · Cited by 23
“C-reactive protein (CRP) is a component of the inflammatory pathway that is dramatically elevated during inflammatory processes and is a useful biomarker for the prognosis of CRC patients [11,12].”
BackgroundCassinotti, A., Keshav, S., Ardizzone, S., Mortensen, N. J. M., Sampietro, G. M., Fociani, P., Duca, P., George, B. D., Lazzaroni, M., Manes, G., et al. (2009) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2009.08.002 · Cited by 21
Targeting IL-6 in Cholangiocarcinoma Therapy
Mott, J. L., & Gores, G. J. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01394.x · Cited by 20
“Creactive protein (CRP), a hepatic gene target of IL-6 signaling cascades (8), perhaps would be even a more useful marker for this inflammatory cancer, an idea which warrants study.”
BackgroundFrom Homeostasis To Inflammation To Autoimmunity: The Potential Impact of CRP
Ahmed, M. J., Yuan, P., Lei, J.-G., Tang, Z.-M., Yang, Z.-R., Potempa, L. A., Wang, H., & Li, H. (2025) · Inflammation · doi:10.1007/s10753-025-02303-7 · Cited by 23
“CRP peptides 174–185 and 201–206 hinder neutrophil-endothe-lial adhesion by binding to receptors on neutrophils, preventing neutrophil chemotaxis [87, 88]. mCRP inhibits neutrophil adhesion by binding to FcγRIII (CD16) on neutrophils, preventing L-selectin shedding and subsequent adhesion [89].”
Iaculli, E., Agostini, M., Biancone, L., Fiorani, C., Divizia, A., Montagnese, F., Sibio, S., Manzelli, A., Tesauro, M., Rufini, A., et al. (2016) · Cell Death Discovery · doi:10.1038/cddiscovery.2016.32 · Cited by 19
The use of fecal calprotectin and lactoferrin in patients with IBD. Review.
Stragier, E., & G, V. A. (2013) · PubMed · Cited by 18
The quantitative validation of non‐endoscopic disease activity indices in ulcerative colitis
Higgins, P. D. R., Leung, J., Schwartz, M. B., Mapili, J., Wren, P. A., & Zimmermann, E. M. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03205.x · Cited by 18
Moran, M. M., Wessman, P., Rolfson, O., Bohl, D. D., Kärrholm, J., Keshavarzian, A., & Sumner, D. R. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257310 · Cited by 18
Zhou, Y., Li, D., Lin, Y., Yu, M., Lu, X., Jian, Z., Na, N., & Hou, B. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s152657 · Cited by 16
Domachevsky, L., Leibovitzh, H., Avni‐Biron, I., Lichtenstein, L., Goldberg, N., Nidam, M., Groshar, D., Bernstine, H., & Ben‐Bassat, O. (2017) · Contrast Media & Molecular Imaging · doi:10.1155/2017/7167292 · Cited by 16
Putchakayala, K. G., Polensky, S., Fitzhugh, J., Cohran, V. C., Buchman, A. L., & Fryer, J. P. (2008) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607108322395 · Cited by 13
Matthes, A., Wolf, F., Wilde, E., Bleidorn, J., & Markwart, R. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-069453 · Cited by 10
Influence of the Gut Microbiota on Blood Acute‐Phase Proteins
Schroedl, W., Kleessen, B., Jaekel, L., Shehata, A. A., & Krueger, M. (2014) · Scandinavian Journal of Immunology · doi:10.1111/sji.12161 · Cited by 12
Small-Bowel Capsule Endoscopy—Optimizing Capsule Endoscopy in Clinical Practice
O'Hara, F. J., & McNamara, D. A. (2021) · Diagnostics · doi:10.3390/diagnostics11112139 · Cited by 12
“A raised CRP broadly correlates with clinical severity in CD [5,6].”
BackgroundMonitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis
Ge, C., Lü, Y., Shen, H., & Zhu, L. (2022) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2021.2022193 · Cited by 13
“occurs, liver cells will express CRP increases rapidly under the influence of IL-1b, potentially reaching a peak of 350–400mg/l [68,69].”
BackgroundCho, J.-H., Lee, D., & Lee, H. J. (2022) · Toxics · doi:10.3390/toxics10090533 · Cited by 12
Astegiano, M., Pagano, N., Sapone, N., Simondi, D., Bertolusso, L., Bresso, F., Demarchi, B., Pellicano, R., Bonardi, R., Marconi, S., et al. (2007) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2007.02.013 · Cited by 11
Bathe, A. L., Mavropoulou, E., Mechie, N.-C., Petzold, G., Ellenrieder, V., Kunsch, S., & Amanzada, A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223893 · Cited by 11
“This result is consistent with results from other studies [30, 31].”
ResultEndotoxin Neutralization as a Biomonitor for Inflammatory Bowel Disease
Champion, K., Chiu, L. S., Ferbas, J., & Pepe, M. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067736 · Cited by 10
Kartik, A., Müller, C., Acs, M., Piso, P., Starlinger, P. P., Bachleitner‐Hofmann, T., & Grotz, T. E. (2023) · Pleura and Peritoneum · doi:10.1515/pp-2022-0203 · Cited by 9
“Low cost, easy availability, non-invasiveness of the test and, promising data from previous studies were some of the factors why CRP was chosen as the inflammatory marker for our study [12].”
MethodLiu, C., Shatila, M., Mathew, A., Machado, A. P., Thomas, A. R., Zhang, H. C., Thomas, A. S., Faleck, D. M., Funchain, P., Philpott, J. R., et al. (2023) · Journal of Cancer · doi:10.7150/jca.84261 · Cited by 9
“For example, in systemic lupus erythematosus, biomarkers such as IL-18 and TNFα are preferred over CRP for disease monitoring [14].”
BackgroundThe Analysis of Factors Associated with Progression of Isolated Terminal Ileal Lesions
Zhang, F., Weiwei, H., Wugan, Z., Cong, Z., Yanjun, C., & Xu, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090797 · Cited by 9
Markwart, R., Lehmann, L.-S., Krause, M., Jung, P., Rost, L., Doepfmer, S., Kümpel, L., Kuschick, D., Toutaoui, K. J., Heintze, C., et al. (2024) · BJGP Open · doi:10.3399/bjgpo.2024.0120 · Cited by 8
“7,9,10,12,37,43 Similar to the UK, the relatively low uptake of CRP-POCTs in Germany can be attributed to time constraints, effects on clinical workflow, and costs.”
Dignass, A. U., Eliakim, R., Magro, F., Maaser, C., Chowers, Y., Geboes, K., Mantzaris, G. J., Reinisch, W., Colombel, J. F., Vermeire, S., et al. (2014) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2014.10.001 · Cited by 13
Self-citationWang, Y., & Li, L. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6577 · Cited by 7
Ware, W. R. (2010) · Cited by 6
Shamohammadi, M., Yarahmadi, D., Yiasemidou, M., Teymoori, M. H., Rouzbahani, A. K., Bahrdoust, M., & Garavand, A. A. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01446-6 · Cited by 6
Metadata
- Authors
- Vermeire, S., Van Assche, G., & Rutgeerts, P.
- Affiliations
- Universitair Ziekenhuis Leuven (BE)
- Corresponding author
- Vermeire, Séverine
- ORCID
- Vermeire, Séverine
- Venue
- Nature Clinical Practice Gastroenterology & Hepatology
- Published
- 2005-12
- Volume
- 2
- Issue
- 12
- Pages
- 580-586
- ISSN
- 1743-4378 (ISSN-L)
- 1743-4386
- OpenAlex
- W2036630215
- Cited by
- 149
- References
- 51
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 6 · 2023: 7 · 2022: 7 · 2021: 8 · 2020: 8 · 2019: 9 · 2018: 10 · 2017: 6 · 2016: 8 · 2015: 6 · 2014: 9 · 2013: 9 · 2012: 6
- FWCI
- 0.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Clinical Practice Gastroenterology & Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
- Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
- Keywords
- C-reactive protein, inflammatory markers, gastrointestinal inflammation, Crohn's disease, ulcerative colitis, acute pancreatitis, disease activity monitoring, colorectal cancer risk, anti-TNF therapy, acute phase response, interleukin-6, TNF-α
- MeSH terms
- C-Reactive Protein, Gastrointestinal Diseases, Humans, Inflammation, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.